


Acute and chronic glomerulonephritis in children



Associate professor Kazyra I.A.

1st Department of Pediatrics BSMU

Glomerulonephritis (GN)

Heterogeneous group of disorders with an initial renal glomerular lesion (later in the disease process may involve other renal structures - tubules, vessels, interstition), having different etiology, pathogenesis, clinical and morphological manifestations, course and outcome.

Glomerulonephritis (GN)

Primary (idiopathic) – the actual primary glomerular disease

Secondary (developing in a number of systemic connective tissue diseases - systemic lupus erythematosus, systemic vasculitides, etc.).

Glomerulonephritis (GN)

Although at present the morphological differentiation of GN is considered the most correct than clinical classification, it's still widely used in everyday clinical pediatric practice – Vinniza classification of GN 1976 y.

Despite the fact that there is overlap between the clinical and histological variants GN only

morphological verification allows correct the diagnosis and hold the most appropriate therapy and monitoring the disease.

Glomerulonephritis (GN)

Clinical classification:

- ***Acute***
- ***Chronic***
- ***Rapidly progressive (RPGN)***

Classification, Vinniza 1976

Form of GN	Activity	Kidney function
<p><i>Acute GN with</i></p> <ul style="list-style-type: none"> ● nephritic syndrome ● nephrotic syndrome ● urinary syndrome ● mixt – nephrotic syndrome+ hematuria+AG 	<ul style="list-style-type: none"> ● manifestation ● recovery ● transformation in chronic 	<ul style="list-style-type: none"> ● normal ● with kidney impairment ● Acute renal failure (kidney injury)

Classification, Vinniza 1976

Form	Activity	Kidney function
<p><i>Chronic GN :</i></p> <ul style="list-style-type: none">● nephrotic form● hematuric● mixt	<ul style="list-style-type: none">● relapse● partial remission● complete clinical and laboratory remission	<ul style="list-style-type: none">● without kidney impairment● with kidney impairment● CRF (CKD)

Classification, Vinniza 1976

Form	Activity	Kidney function
<p data-bbox="198 586 649 805"><i>Rapidly progressive,</i></p> <p data-bbox="316 891 537 953"><i>RPGN</i></p> <p data-bbox="369 1048 484 1110"><i>GN</i></p>		<ul data-bbox="1180 586 1760 1248" style="list-style-type: none"><li data-bbox="1180 586 1624 805">● with renal impairment<li data-bbox="1180 891 1760 1248">● Chronic renal failure (kidney disease)

Glomerulopathies / nephritis

Non-immune

- Minimal changes;
- Membranous nephropathy;
- Focal glomerulosclerosis (hyalinosis);
segmental FSGS
- Thin membranes
- Diabetic nephropathy;
- Amyloid nephropathy;
- Ischemic nephropathy;

Immune

- Acute poststreptococcal / post infectious GN
- Chronic GN:
 - ❖ proliferative:
 - with «crescents»
 - mesangioproliferative
 - Membranoproliferative
 - ❖ Fibroplastic (sclerotic):
 - focal
 - diffuse

Main mechanisms of glomerular injury

1. No-immune

The changes are degenerative /or dysplastic nature and often reversible

2. Immune

Manifested classic signs of inflammation:


- infiltratio;
- proliferatio;
- exudatio;
- alteratio.

Glomerulonephritis (GN)

Non-inflammatory

(glomerulopathies)

The principal target of the immune attack are visceral epithelial cells of the glomeruli=
podocytopathies




Glomerulonephritis (GN)



Inflammatory (immune GN)

The principal target of the immune attack are endothelium, mesangium, epi-peri-, intramembranouse structures=

Real nephritis




Light microscopy




Immunohistochemistry


MesPrGN





Prolif GN




Memr Pr GN
type I




Membr Pr GN
type II




Acute GN



Membranose GP





Anti-GBM GN




Phybrill GN

Electron microscopy







Acute GN

Acute diffuse immune-inflammatory (mediated) kidney disease, mainly affecting the glomeruli, in which there are **changes in the glomeruli with exudative-proliferative component.**

Prevalence - 0.1 - 0.2%.

More common at the age – 5 -12 years.

Etiology

● Streptococci ("nephritogenic" strains, β -hemolytic group A, type 1, 2, 4, 12, 49, 55 et al.)

Infection of the throat or skin - flu, fever, streptoderma, impetigo etc .;

● Other infections: influenza, viruses etc .;

● Vaccination (often R2, R1);

● Season (February-March, October-November in Belarus).

Predisposing factors

- ***Hereditary predisposition;***
- ***Increased familial susceptibility to streptococcal infection;***
- ***Chronic foci of infection, hypovitaminosis;***
- ***Hypothermia.***

Pathogenesis


- Immune –complex disease.
- The streptococcus produces toxins and enzymes (streptolysin, Hyaluronidase, streptokinase, and others.)
That initiate the production of specific antibodies with the subsequent formation of the immune complexes (IC)
- IC deposited on the glomerular capillary wall, activate complement with further production of proinflammatory mediators of glomerular cells

Pathogenesis

As a result of these processes capillary endothelial lesion occurs with increasing their permeability to blood components such as red blood cells and protein.

An important role play a cross-reaction between streptococcal and glomerular antigens ("antigenic mimicry"), especially the individual features of immune response




III d – immune-complex type of immune-pathological reactions



Pathogenesis

- Intravascular damage – edema → reduced GFR → renin-AT-aldosteron → retention of sodium and water → hyperhydration = edema, blood pressure increased
- Urinary and blood changes
- Light microscopy- exudative-proliferative changes in glomeruli .
- EM, IF –IgG or M, C3-complement deposts;
- 6 months duration of changes.

LM, IF, silver



Clinic of acute PSGN

- Acute onset of the disease after 1-3 weeks after preceding of streptococcal infection.
- Typical acute nephritic syndrome:
- Mild proteinuria (1 - 2 g / l);
- Hematuria from the micro to the macrohematuria ("meat slops", "Coca-Cola" or "beer");
- Cellular casts (hyaline and erythrocyte);
- oliguria;
- Moderate edema of the eyelids, face, at least - shins;
- Hypertension.
- The prognosis is favorable (recovery up to 95% of patients)

Clinic

Extrarenal manifestations.

- moderate edema ;
- ↑ BP, tachy- or bradycardia;

- Acute manifestation: headache;
- nausea, vomiting;
- deterioration of general condition;
- decreased appetite;
- change in urine color (brown, the color of beer, cola)
- lower back pain;
- brain syndrome - convulsions, insomnia, autonomic dysfunction.

Labs

Blood.

- anemia
- Lei↑
- neutrophils ↑
- ESR ↑

Serology:

- ↑ASLO

Immunology

- C3-complement ↓ - especially during follow-up

Indications for kidney biopsy

- Clinically, a classic manifestation of AGN is nephritic syndrome, although not an exception are other clinical syndromes - nephrotic (NS), NS with hematuria and hypertension, isolated urinary syndrome.
- In typical cases of AGN biopsy is not required.
- ***Morphological examination is necessary in atypical manifestations and / or long-term preservation of symptoms.***

Indications for kidney biopsy

- **Suspected RPGN (severe proteinuria, hematuria, the rapid growth of creatinine, blood urea, oliguria)**
- **Suspected kidney disease in the frame of systemic diseases (SLE, systemic vasculites etc.)**
- **Low C3-complement over 2-3 months**
- **Persistent proteinuria of more than 6 months**
- **Hematuria +proteinuria persistant**

Treatment

Basic therapy:

- regimen- bed at the time of edema;
- diet (salt restriction, fluid and spice restriction);
- antibacterial - penicillin or cephalosporins of I-th generation, or macrolides for 10-14 days;
- syndromal therapy

Treatment

Syndromic therapy:

- Antihypertensive - Nifedipine 0.25-0.5 mg / kg / day, amlodipine and 0.06 mg / kg / day, β -blockers, α , β -Blockers
- **NB! Carefully ACE inhibitors - captopril, enalapril – high potassium!**
- Diuretics - furosemide 1-2 mg / kg
- Antiplatelet agents - dipyridamole, curantil, Trental

Rapidly progressive GN with «crescents» - malignant

Etiology

Idiopathic, postinfectious, in systemic diseases.

Pathogenesis:

Immune-complex, antibody mediated.


Morphology:

Proliferation of the epithelium of the out-layer of the capsule Shymlansky-Bowman with the

formation of crescents in more than 50% of the glomeruli.


RPGN

Cellular crescents



RPGN

Fibrous crescents



Clinic

- Severe with extremely high activity;
- Rapid increase in renal failure (often irreversible), with the development of end-stage renal failure within a few weeks or months.
- Biopsy shown at the first suspicion of rapidly progressive glomerulonephritis.
- Outcome: Unfavorable.

Treatment

Immediate prescription of aggressive immunosuppressive therapy!

Pulse therapy with methylprednisolone (30 mg / kg per day to 1000 mg per administration) or cyclophosphamide (500-750 mg / m² per administration) - 3-5 sessions performed in synchronization with plasmapheresis:

🌐 Day – medication prescription, next day - removal of plasma (source of pro-inflammatory immune mediators, cytokines, antibodies, etc.).

🌐 Red blood returned to the patient, the plasma is removed

Treatment

prescription of aggressive immunosuppressive therapy!

- After pulse therapy with plasmapheresis - immunosuppressive therapy is administered orally (prednisolon 2 mg / kg / day + cytostatic) in combination with anticoagulants (heparin, Fragmin, aspirin, etc.),
And antiplatelets.
- In severe cases may require dialysis (hemodialysis, hemodiafiltration, and so on.).

Chronic GN

Chronic GN (GN) – a group of chronic glomerulopathies, most immune-mediated, mainly affecting the glomerulus, with different clinical and morphological picture, course and outcome.

ORIGIN:

**A consequence of acute glomerulonephritis (rare!)
More often - the so-called primary chronic form).**

Morphological classification of GN

Non-proliferative (non-inflammatory):

- Minimal change nephropathy;
- Membranous nephropathy;
- Focal segmental glomerulosclerosis.

Proliferative(inflammatory):

- Mesangioproliferative glomerulonephritis;
- Membranoproliferative glomerulonephritis;
- Fibroplastic glomerulonephritis.

Minimal change disease (nephropathy)

Light microscopy:

Without changes.

IF / IGH:


negative.

Electron microscopy:

absent of small feet podocyte processes (fusion) or merge them.


Minimal change disease

Light microscopy





Minimal change disease

Electron microscopy



Minimal change disease

Electron microscopy



Minimal change disease

Clinic:

- Nephrotic syndrome (75-80% of the nephrotic syndrome in children).
- Mostly in infants and preschool children (2-7 years) with a history or allergy.
- More common in boys (2: 1).
- High sensitivity to corticosteroids.

Outcome:

In most cases favorable.

Nephrotic syndrome

4 signs

- 1. Massive proteinuria ($> 3\text{g} / \text{L}$ or $> 50\text{ mg} / \text{kg}$ per day, or $\uparrow 40\text{ mg} / \text{m}^2 \times \text{h}$ or protein-to-creatinine ratio in morning urine $> 0.2\text{ mg} / \text{mmol}$)**
- 2. Low total protein $< 60\text{ g} / \text{l}$ in combination with low albumin $< 30\text{ g} / \text{l}$ (characterized by increased α_2 -globulins and decreased gamma globulins).**
- 3. Hyperlipidemia (Cholesterol $> 5,2\text{mmol} / \text{l}$)**
- 4. Severe peripheral and abdominal swelling (ascites, hydropericardium, hydrothorax) till anasarca.**

Nephrotic syndrome



Morphological changes in nephrotic syndrome in children

- **Glomerulonephritis with minimal changes.**
- **FSGS (focal segmental glomerulosclerosis)**
- **Membranous glomerulonephritis.**
- **membranoproliferative GN**

NS - treatment

prednisolone

60 mg / m² (2mg / kg, but not more than 80 mg per day) during 4 weeks (duration may be up to 6 weeks)

Then alternating regimen:

60 mg / m² every other day - 8 weeks;

45mg / m² every other day - 2 weeks;

30 mg / m² every other day - 2 weeks;

15 mg / m² every other day - 2 weeks.

The total duration of treatment is 4-5 months.

Nephrotic syndrome - options for response to treatment GCS

1. Steroid-sensitive - complete remission with prednisolone at a standard dose achieved in 4-6 weeks.

1.1 Steroid-dependent - NS relapse during treatment with prednisolone or within 2 weeks after its cancellation.

1.2 Frequently relapsing - 2 or more relapses within 6 months or 3 or more relapses within a year.

Nephrotic syndrome - options for response to treatment GCS

2. Steroid-resistant – lack of complete clinical and laboratory remission with prednisolone at a standard dose within 4 - 6 weeks (renal biopsy?) or after pulse therapy with methylprednisolone at a dose of 30 mg / kg per administration for 3 consecutive days

Treatment of steroid-dependent NS

Chlorambucil (leykeran) - 0.2 mg / kg per day 8-12 weeks - today rarely used !;

***Cyclophosphamide - 2 mg / kg per day to 8 weeks;
Cyclosporin A - 4 - 6 mg / kg per day in 2 divided doses (doses under the control serum concentration - 80 - 150 ng / ml)***

in combination with prednisone 1 mg / kg / every other day

Treatment of steroid-resistant NS

Cyclosporin A (4-6 mg / kg / day in combination with prednisone 1 mg / kg / 48 hours), then to 18-24 months monotherapy

Mycophenolate mofetil (MMF)

Tacrolimus;

Alkylating agents (chlorambucil, cyclophosphamide);

Protocol MENDOZA;

ACE inhibitors or

Angiotensin receptor antagonists

Treatment of steroid-resistant NS

ACE inhibitors (enalapril 0.05 to 0.5 mg / kg) administered in nephrology in order to reduce the damaging effect of the proteinuria on renal tubule epithelium, decrease GFR and thus proteinuria = nephroprotective effect;

OR angiotensin receptor antagonists (losartan 100 mg / day, irbersartan 75-150 mg / day).

You can not assign at the same time both of them because of the risk of increasing potassium!

MENDOZA Protocol

<i>Weeks</i>	<i>IV Methylprednisolone</i>	<i>Prednisolone orally</i>
1-2	30 mg/kg/daily alternate day	—
3-10	30 mg/kg 1 time per week	2 mg/kg alternate day
11-18	30 mg/kg через неделю	2 mg/kg alternate day
19-52	30 mg/kg в месяц	2 mg/kg alternate day
53-78	30 mg/kg alternate day	2 mg/kg alternate day

Indications for biopsy in NS

- **Steroid-resistant NS**
- **Steroid-dependent and often recurrent NS (3-rd relapse).**
- **NS with hematuria and hypertension.**
- **The patient's age up to 1 year (genetic research?) And older than 12 years.**
- **Cyclosporin A treatment for more than 6 months (with an increase in creatinine, decreased density of urine = cyclosporin nephrotoxicity?)**

Indications for biopsy in NS

- **The patient's age up to 1 year - mostly genetic causes (Congenital NS can not be treated with CS and cytostatics - treatment more harmful than goodness!)**
- **Over 12 years - a suspicion of secondary damage of the kidneys through a systemic process - therapy should be more aggressive!**

NS with hypertension and hematuria

**Combines the clinical manifestations of nephrotic and nephritic disease variants, but:
swelling less pronounced, but more resistant;
increased blood pressure;
hematuria;
anemia;
increase in γ - globulins.**

NS - Treatment

Together with corticosteroids prescribed

- **Proton pump inhibitors - omeprazole, children up to 5 years – Gefal**
- **For the prevention of osteoporosis – calcium + vitamin D**
- **Limited salt, liquid account**
- **Control of blood pressure, blood glucose**
- **eye exam**

NS - Complications

- **Hypovolemia - albumin intravenously when serum levels lower than 20 g / l and / or abdominal ascites**
- **Hyper coagulation (thrombosis) - heparin, aspirin**
- **Infection - intravenous immunoglobulin**
- **Hyperlipidemia - diet**
- **Protein-energy malnutrition**
- **Prolonged therapy with corticosteroids....**

Steroid side-effects

- **Erosive and ulcerative lesions of the gastrointestinal tract**
- **Sodium and fluid retention**
- **Hypertension**
- **Hyperglycemia, steroid diabetes**
- **Cushing's syndrome**
- **Violation of mineral metabolism**
- **Physical, sexual development delay**
- **immunodeficiency**
- **cataract....**

***Focal-segmental
glomerulosclerosis/ hyalinosis
FSGS***

Clinically:

more often steroid-resistant nephrotic syndrome


FSGS

LM: focal (some glomeruli) and segmental (part of glomerular capillary loops) glomerulosclerosis and / or hyalinosis.


EM: in sclerosed segments - collapse of capillary loops, obliteration of the lumen (insudative changes); in other glomeruli – fusion of small processes podocytes.

IF: in sclerosed segments - IgM, C3; in unchanged glomeruli – negative.

FSGS



FSGS



FSGS - Treatment

Cyclosporin A - 4 - 7 mg / kg per day in combination with prednisone 1 mg / kg every other day for at least 18 months (25-40% remission, but there has been rapid relapse of nephrotic syndrome after discontinuation of treatment);

Protocol MENDOZA.

Recurrence in the graft - a special protocol for management of the recipient after kidney Tx!

Membranous nephropathy


LM: diffuse thickening of the glomerular capillaries of BM. When silvered BM uneven contours with the emergence of numerous spines (diagnostic feature).

EM: subepithelial deposits, which are walled up in membranous-dense substance produced by podocytes - "membranous transformation".

IF: peripheral granular deposits of IgG and C3, rarely IgM, rarely IgA.


Membranous nephropathy

Light microscopy




Membranous nephropathy

Light microscopy - Silver




Membranous nephropathy

IF microscopy



Membranous nephropathy

Electron microscopy



Membranous nephropathy

Etiology:

Idiopathic - 50%;

Secondary - 50% (hepatitis B, malaria, syphilis, tumors, captopril).

Pathogenesis: Immune-complexe.

Clinic:

7% of the children glomerulopathies;

More common in school age children;

Isolated proteinuria, hematuria+ proteinuria or nephrotic syndrome + hematuria;

Steroid-resistant

Outcome:

The high frequency of spontaneous remissions;

Rare progression to ESRD (for 5 years - 5%).

Membranous nephropathy

- **No controlled studies in children for the treatment;**
- **In isolated proteinuria - ACE inhibitors, observation;**
- **With the development of nephrotic syndrome and progression:**
 - **Long-term use of corticosteroid therapy alternating scheme (years);**
 - **Chlorambucil, cyclophosphamide, cyclosporin A, ACE inhibitors; monoclonal antibodies (rituximab)**
 - **Treatment of the underlying disease, against which there was nephropathy (hepatitis B, etc.).**

Mesangioproliferative GN


LM: mesangial expansion due to the proliferation of mesangial cells.

EM: an increase in mesangial matrix, mesangial deposits.

IF: granular diffuse of mesangial deposits of IgG, M, A, C3 -complement.

Clinically - hematuric or nephrotic form


Mesangial proliferation




IgA-nephropathy

It's mesangio-proliferative GN with prevailing deposits of IgA (IgA-nephropathy)

IgA-nephropathy



IgA-nephropathy



IgA-nephropathy

Etiology:

In children often idiopathic;
Less common secondary – SHP vasculitis, bowel disease and so on.

Clinic:

In typical cases, recurrent gross (macro) hematuria, often provoked by ART infection. Between the previous infection and recurrent gross hematuria is usually no more than 1-2 days.

Less commonly nephrotic syndrome.

IgA-nephropathy

Outcome:

Previously it was thought that the disease is benign, but according to adults nephrologists data in 30-35% of patients the progression to ESRD is happened between 20-30 years.

IgA-nephropathy

With isolated hematuria only observation;

In Nephrotic syndrome:

steroids (60-30-15mg / m² for 3-5 years)

Omega -3 fatty acids (fish oil 4 g for 2 years)

ACE inhibitors for long-time

Mesangiocapillary GN

LM: diffuse thickening and splitting of GBM with expression of mesangial cells / proliferation.

EM: splitting of GBM, increased mesangial matrix and cellularity.

IF: peripheral, large, confluent deposits of C3, rarely IgG, IgA, C4, fibrin.

Mesangiocapillary GN





● 3 types on morphology:





● Type I – sub-endothelial deposits

● Type II - "dense" deposits disease (at present - isolated in a separate disease)

● Type III - transmembrane deposits

● Clinical differences between the three types is not detected: edema in conjunction with hematuria and / or hypertension, hematuria, isolated urinary syndrome, or mixed NS).





Mesangiocapillary GN

Etiology: almost always idiopathic

Clinic: highly variable (differential diagnosis - acute nephritic syndrome)

C3 - hypo-complementemic GN

Suffer more school-age children, boys: girls = 1: 1

The lack of effect on the standard therapy of GCS

Outcome:

Progressive course with the development of ESRD (10-year survival rate of 32%)

High risk of recurrence in the graft!

Mesangiocapillary GN

- 1. No standard treatment;**
- 2. When an isolated hematuria - just an observation;**
- 3. In NS- long steroids therapy - within 1-5 years, possibly after pulse therapy with corticosteroids**
- 4. Cyclosporine A**
- 7. ACE inhibitors with antiproteinuric and renoprotective purpose for long-time**

Thank you for your attention!

